Patents by Inventor Robert W. Chesnut

Robert W. Chesnut has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HLA-A2 tumor associated antigen peptides and compositions
    Patent number: 9913884
    Abstract: A peptide or composition comprising at least one HLA-A2 epitope or analog from CEA, HER2/neu, MAGE2, MAGE3, or p53.
    Type: Grant
    Filed: June 28, 2016
    Date of Patent: March 13, 2018
    Assignee: OSE Pharma International SA
    Inventors: John D. Fikes, Glenn Ishioka, Alessandro Sette, Robert W. Chesnut
  • HLA-A2 TUMOR ASSOCIATED ANTIGEN PEPTIDES AND COMPOSITIONS
    Publication number: 20170028041
    Abstract: A peptide or composition comprising at least one HLA-A2 epitope or analog from CEA, HER2/neu, MAGE2, MAGE3, or p53.
    Type: Application
    Filed: June 28, 2016
    Publication date: February 2, 2017
    Inventors: John D. Fikes, Glenn Ishioka, Alessandro Sette, Robert W. Chesnut
  • HLA-A2 tumor associated antigen peptides and compositions
    Patent number: 9394350
    Abstract: A peptide or composition comprising at least one HLA-A2 epitope or analog from CEA, HER2/neu, MAGE2, MAGE3, or p53.
    Type: Grant
    Filed: November 15, 2013
    Date of Patent: July 19, 2016
    Assignee: OSE PHARMA INTERNATIONAL SA
    Inventors: John D. Fikes, Glen Ishioka, Alessandro Sette, Robert W. Chesnut
  • HLA-A2 TUMOR ASSOCIATED ANTIGEN PEPTIDES AND COMPOSITIONS
    Publication number: 20140141064
    Abstract: A peptide or composition comprising at least one HLA-A2 epitope or analog from CEA, HER2/neu, MAGE2, MAGE3, or p53.
    Type: Application
    Filed: November 15, 2013
    Publication date: May 22, 2014
    Inventors: JOHN D. FIKES, GLEN ISHIOKA, ALESSANDRO SETTE, ROBERT W. CHESNUT
  • HLA-A2 TUMOR ASSOCIATED ANTIGEN PEPTIDES AND COMPOSITIONS
    Publication number: 20120183598
    Abstract: A peptide or composition comprising at least one HLA-A2 epitope or analog from CEA, HER2/neu, MAGE2, MAGE3, or p53.
    Type: Application
    Filed: August 18, 2011
    Publication date: July 19, 2012
    Inventors: John D. Fikes, Glenn Ishioka, Alessandro Sette, Robert W. Chesnut
  • HLA-A2 tumor associated antigen peptides and compositions
    Patent number: 8007810
    Abstract: A peptide or composition comprising at least one HLA-A2 epitope or analog from CEA, HER2/neu, MAGE2, MAGE3, or p53.
    Type: Grant
    Filed: February 23, 2010
    Date of Patent: August 30, 2011
    Assignee: Biotech Synergy, Inc.
    Inventors: John D. Fikes, Glenn Ishioka, Alessandro Sette, Robert W. Chesnut
  • Inducing cellular immune responses to hepatitis B virus using peptide and nucleic acid compositions
    Publication number: 20110097352
    Abstract: This invention uses our knowledge of the mechanisms by which antigen is recognized by T cells to develop epitope-based vaccines directed towards HBV. More specifically, this application communicates our discovery of pharmaceutical compositions and methods of use in the prevention and treatment of HBV infection.
    Type: Application
    Filed: October 30, 2007
    Publication date: April 28, 2011
    Applicant: Pharmexa Inc.
    Inventors: Alessandro Sette, John Sidney, Scott Southwood, Maria A. Vitiello, Brian D. Livingston, Esteban Celis, Ralph T. Kubo, Howard M. Grey, Robert W. Chesnut
  • HLA-A2 Tumor Associated Antigen Peptides and Compositions
    Publication number: 20100209493
    Abstract: A peptide or composition comprising at least one HLA-A2 epi tope or analog from CEA, HER2/neu, MAGE2, MAGE3, or p53.
    Type: Application
    Filed: February 23, 2010
    Publication date: August 19, 2010
    Applicant: IDM Pharma, Inc.
    Inventors: John D. FIKES, Glenn Ishioka, Alessandro Sette, Robert W. Chesnut
  • PEPTIDES FOR INDUCING A CTL AND/OR HTL RESPONSE TO HEPATITIS C VIRUS
    Publication number: 20100099613
    Abstract: The present invention is directed to peptides, and nucleic acids encoding them, derived from the Hepatitis C Virus (HCV). The peptides are those which elicit a CTL and/or HTL response in a host. The invention is also directed to compositions and vaccines for prevention and treatment of HCV infection and diagnostic methods for detection of HCV exposure in patients.
    Type: Application
    Filed: October 6, 2009
    Publication date: April 22, 2010
    Applicants: GENIMMUNE, PHARMEXA INC.
    Inventors: Marie-Ange Buyse, Geert Maertens, Erik Depla, Ignace Lasters, Johan Desmet, Denise Baker, Robert W. Chesnut, Mark Newman, Alessandra Sette, John Sidney, Scott Southwood
  • Inducing cellular immune responses to hepatitis B virus using peptide and nucleic acid compositions
    Publication number: 20090311283
    Abstract: This invention uses our knowledge of the mechanisms by which antigen is recognized by T cells to develop epitope-based vaccines directed towards HBV. More specifically, this application communicates our discovery of pharmaceutical compositions and methods of use in the prevention and treatment of HBV infection.
    Type: Application
    Filed: October 30, 2007
    Publication date: December 17, 2009
    Applicant: Pharmexa Inc.
    Inventors: Alessandro Sette, John Sidney, Scott Southwood, Maria A. Vitiello, Brian D. Livingston, Esteban Celis, Ralph T. Kubo, Howard M. Grey, Robert W. Chesnut
  • Hla-A2 Tumor Associated Antigen Peptides and Compositions
    Publication number: 20080274129
    Abstract: A peptide or composition comprising at least one HLA-A2 epitope or analog from CEA, HER2/neu, MAGE2, MAGE3, or p53.
    Type: Application
    Filed: April 16, 2004
    Publication date: November 6, 2008
    Inventors: John D. Fikes, Glenn Ishioka, Alessandro Sette, Robert W. Chesnut
  • Inducing cellular immune responses to hepatitis B virus using peptide and nucleic acid compositions
    Patent number: 6689363
    Abstract: This invention uses our knowledge of the mechanisms by which antigen is recognized by T cells to develop epitope-based vaccines directed towards HBV. More specifically, this application communicates our discovery of pharmaceutical compositions and methods of use in the prevention and treatment of HBV infection.
    Type: Grant
    Filed: January 27, 1999
    Date of Patent: February 10, 2004
    Assignee: Epimmune Inc.
    Inventors: Alessandro Sette, John Sidney, Scott Southwood, Maria A. Vitiello, Brian D. Livingston, Esteban Celis, Ralph T. Kubo, Howard M. Grey, Robert W. Chesnut
  • Expression vectors for stimulating an immune response and methods of using the same
    Publication number: 20030216343
    Abstract: The present invention relates to nucleic acid vaccines encoding multiple CTL and HTL epitopes and MHC targeting sequences.
    Type: Application
    Filed: February 21, 2003
    Publication date: November 20, 2003
    Inventors: John D. Fikes, Gary G. Hermanson, Alessandro Sette, Glenn Y. Ishioka, Brian Livingston, Robert W. Chesnut
  • Compositions and methods for eliciting CTL immunity
    Publication number: 20030099634
    Abstract: Cytotoxic T lymphocyte responses are effectively induced to an antigen of interest, particularly viral, bacterial, parasitic and tumor antigens. Compositions, including pharmaceutical compositions, of CTL-inducing peptide and an adjuvant or a lipidated peptide which induces a helper T cell (HTL) response stimulate the antigen specific CTL response. Among the viral antigens to which the CTL responses are effectively induced in humans are those of hepatitis B. The CTL response may be optimized by a regimen of two or more booster administrations. Cocktails of two or more CTL inducing peptides are employed to optimize epitope and/or MHC class I restricted coverage.
    Type: Application
    Filed: April 22, 2002
    Publication date: May 29, 2003
    Inventors: Maria A. Vitiello, Robert W. Chesnut, Alessandro D. Sette, Esteban Celis, Howard Grey
  • Expression vectors for stimulating an immune response and methods of using the same
    Patent number: 6534482
    Abstract: The present invention relates to nucleic acid vaccines encoding multiple CTL and HTL epitopes and MHC targeting sequences.
    Type: Grant
    Filed: May 13, 1999
    Date of Patent: March 18, 2003
    Assignee: Epimmune, Inc.
    Inventors: John D. Fikes, Gary G. Hermanson, Alessandro Sette, Glenn Y. Ishioka, Brian Livingston, Robert W. Chesnut
  • HLA-restricted hepatitis B virus CTL epitopes
    Patent number: 6322789
    Abstract: Cytotoxic T lymphocyte-stimulating peptides induce HLA-restricted responses to hepatitis B virus antigens. The peptides, derived from CTL epitopic regions of both HBV surface and nucleocapsid antigens, are particularly useful in the treatment and prevention of HBV infection, including the treatment of chronically infected HBV carriers. The peptides can be formulated as HBV vaccines and pharmaceutical compositions, such as lipid-containing compositions for enhancing the HLA-restricted CTL responses. The peptides are also useful in diagnostic methods, such as predicting which HBV-infected individuals are prone to developing chronic infection.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: November 27, 2001
    Assignee: Epimmune, Inc.
    Inventors: Maria A. Vitiello, Robert W. Chesnut
  • Method for detecting the presence of P-selectin
    Patent number: 6033667
    Abstract: The present invention relates to compositions and methods for treating inflammation and other pathological conditions using novel blocking P-selectin antibodies that inhibit adhesion of leukocytes to activated platelets and/or to activated vascular endothelium in vivo. Both murine and humanized antibodies are provided.
    Type: Grant
    Filed: November 5, 1997
    Date of Patent: March 7, 2000
    Assignee: Cytel Corporation
    Inventors: Robert W. Chesnut, Margaret J. Polley, James C. Paulson, S. Tarran Jones, Jose W. Saldanha, Mary M. Bendig, Michael Kriegler, Carl Perez, Robert Bayer, Michael Nunn